NYXH
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Its lead solution, Genio, uses hypoglossal nerve stimulation as an alternative to CPAP therapy to treat OSA, the world's most common sleep-disordered breathing condition. The company emphasizes relief from CPAP intolerance and aims to improve sleep health with implantable neuromodulation technologies, and it is headquartered in Mont-Saint-Guibert, Belgium, with activities described globally across the sleep medicine field.
No recent news for this company.
No recent deals for this company.